Shares of Canadian cannabis producer CannTrust Holdings (NYSE:CTST,TSX:TRST) dipped following the pricing of a public offering led by US banks.

The company finished the trading session on Thursday (May 2) with a drop in value of 13.06 percent in New York, closing at a price of US$5.59.


CannTrust priced its offering at US$5.50 per share for total gross proceeds of US$170 million.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

In Toronto, shares of CannTrust also declined by double digits. CannTrust finished the day with a price of C$7.58 per share, representing a 12.57 percent loss in value.

“In connection with the offering, the company and the selling shareholders have granted to the underwriters a 30 day option to purchase up to an additional 4,636,363 and 818,182 common shares, respectively, at the public offering price, less the underwriting discount,” CannTrust indicated.

CannTrust originally announced the offering on April 22 and confirmed the book-running managers for the deal included top US banks such as BofA Merrill Lynch, a division of Bank of America (NYSE:BAC), and Citigroup (NYSE:C).

The rest of the underwriters are Credit Suisse Securities, Jefferies (NYSE:JEF), Canaccord Genuity (TSE:CF,OTC Pink:CCORF) and RBC Capital Markets, a division of Royal Bank of Canada (NYSE:RC,TSX:RC).

CannTrust expects the transaction to close on Monday (May 6) and will use the proceeds from the deal for general business operations, including its pursuit of a good manufacturing process certification.

Justin Ort, partner at Measure8 Venture Partners, told Bloomberg the offer is too big. His firm is now shorting CannTrust, according to the report.

“As it turns out, a US$200 million offering on a US$650 million market cap is a lot to ask and investors demanded a big discount,” Ort said.

In February, CannTrust became the fourth Canadian marijuana firm to reach the New York Stock Exchange.

“There’s no doubt in my mind that investors all around the world, in particular institutional investors, have an increasing awareness and willingness to enter the cannabis space,” Peter Aceto, CEO of CannTrust, previously told the Investing News Network.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less